Metabolic

Tirzepatide

Dual GIP and GLP-1 receptor agonist. The first “twincretin” to reach the market.

Approved

Overview

Tirzepatide simultaneously activates the receptors of the two main incretin hormones: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. It was evaluated in the SURPASS (type 2 diabetes) and SURMOUNT (obesity) programmes and has a half-life of about five days.

Mechanism of action

Combined agonism at GIP and GLP-1 receptors, affecting insulin secretion, insulin sensitivity, gastric emptying and appetite regulation.

Research areas

Type 2 diabetes
Obesity
Obstructive sleep apnoea
Liver metabolism

Selected references

Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. PubMed ↗
Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503–515. PubMed ↗

More profiles

Full library

Metabolic

Semaglutide

GLP-1 receptor agonist studied in type 2 diabetes and obesity. One of the most investigated peptides of the past decade.

CAS: 910463-68-2
Mol. weight: 4113.6 g/mol

Approved

View profile

Metabolic

Retatrutide

Triple GIP, GLP-1 and glucagon receptor agonist, currently in phase 3 clinical trials.

CAS: 2381089-83-2
Mol. weight: 4731.3 g/mol

Phase 3

View profile

Tissue repair

BPC-157

Pentadecapeptide derived from a gastric juice protein. Widely studied in animal models; human data are scarce.

CAS: 137525-51-0
Mol. weight: 1419.5 g/mol

Preclinical

View profile